<DOC>
	<DOC>NCT00651560</DOC>
	<brief_summary>This study is intended to allow physicians to check the superior clinical efficacy of Vytorin compared to atorvastatin, as the most adequate therapy using the ATP-III goals achievement and cardiovascular risk reduction in adult patients with dislipidemia.</brief_summary>
	<brief_title>Vytorin As Strategy To Reduce Dislipidemia In Adults (0653A-148)</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
	<criteria>Patients Who Voluntary Accept To Participate In The Study After Been Informed By The Doctor And Signed The Informed Consent Form. Any Another Kind Of Contraindication For Use Of Statins Hypersensitivity To Any Of The Active Ingredients Increased Serum Hepatic Enzymes (Over 3 Times Only) Patients With Severe Hepatic Insufficiency Women who are Pregnant or Potentially Pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>